Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD
Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year.Psilocybin could lead to significant, durable improvements in depression.Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes…